Targeted treatment for ER+ breast cancer after CDK4/6 therapy
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are post-menopausal (commonly based on standard menopause guidelines).
- You have ER-positive breast cancer that is metastatic or locally recurring and cannot be cured by surgery/radiation.
- You previously took a CDK4/6 medicine (palbociclib, ribociclib, or abemaciclib) for advanced disease, and you may have had up to 3 treatments after that.
- Your tumor must be ER-positive and HER2-non-amplified (HER2 is low/negative by test results).
- You can provide tumor genetic testing results from after progression, or you agree the study can perform testing on available samples.
- You do not currently have an unstable brain (CNS) cancer problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This Phase 2 study tests whether adding abemaciclib to fulvestrant can slow or shrink ER-positive, HER2-negative metastatic breast cancer. It is mainly for people whose cancer has progressed despite prior treatment with a CDK4/6 inhibitor and an aromatase inhibitor.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.